WuXi Biologics is a Chinese headquartered CDMO that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics’ roots date back to 2010 when it was established as a business unit of WuXi AppTec, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. Since then, WuXi Biologics has focused on establishing state-of-the-art research and manufacturing facilities and building partnerships with pharmaceutical and biotech companies in the space. WuXi Biologics ultimately spun out of WuXi AppTec in 2015, and two years later went public on the Hong Kong Stock Exchange in June 2017. As of 2021, WuXi Biologics has 18 manufacturing sites around the world including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore with a planned total production capacity of 220,000 by 2022 and over 430,000 liters by 2023. In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. Wikipedia